SFRP5 has been shown to be expressed in cardiomyocytes, and SFRP5 is upregulated in cardiomyocyte hypertrophy and plays a key role in reversing the progression of cardiac hypertrophy and cardiomyopathy through the AT1-R/Rho/ROCK 1/JNK signaling pathway. Here, RHO is linked to cardiomyopathy.